LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company developing innovative therapies for the treatment of immune-mediated and metabolic diseases, today announced that the company will host a Research & Development Day from 9:00a.m.

马萨诸塞州列克星敦市——（商业新闻短讯）——Aldeyra Therapeutics，Inc.（纳斯达克：ALDX）（Aldeyra），一家临床阶段的生物技术公司，开发用于治疗免疫介导和代谢疾病的创新疗法，今天宣布该公司将于上午9:00开始举办研发日。

to 1:00p.m. ET on Thursday, April 25, 2024 in New York City..

2024年4月25日，星期四，美国东部时间下午1:00，纽约市。。

Aldeyra will provide an in-depth review of pipeline programs, and the event will feature presentations from members of the Aldeyra senior leadership team.

Aldeyra将对管道项目进行深入审查，活动将包括Aldeyra高级领导团队成员的演讲。

A live audio webcast and slide presentation will be accessible from the “Investors & Media” section of the Aldeyra website at https://ir.aldeyra.com/ for 90 days following the event.

现场音频网络广播和幻灯片演示将可从Aldeyra网站的“投资者与媒体”部分访问，网址为https://ir.aldeyra.com/活动后90天。

About Aldeyra

关于Aldyra

Aldeyra Therapeutics is a biotechnology company devoted to discovering innovative therapies designed to treat immune-mediated and metabolic diseases. Our approach is to develop pharmaceuticals that modulate protein systems, instead of directly inhibiting or activating single protein targets, with the goal of optimizing multiple pathways at once while minimizing toxicity.

Aldeyra Therapeutics是一家生物技术公司，致力于发现旨在治疗免疫介导和代谢疾病的创新疗法。我们的方法是开发调节蛋白质系统的药物，而不是直接抑制或激活单个蛋白质靶标，目的是同时优化多种途径，同时最大限度地降低毒性。

Our product candidates include RASP (reactive aldehyde species) modulators ADX‑629, ADX‑246, ADX‑248, and chemically related molecules for the potential treatment of systemic and retinal immune-mediated and metabolic diseases. Our late-stage product candidates are reproxalap, a RASP modulator for the potential treatment of dry eye disease and allergic conjunctivitis, and ADX-2191, a novel formulation of intravitreal methotrexate for the potential treatment of retinitis pigmentosa..

我们的候选产品包括RASP（活性醛物质）调节剂ADX-629，ADX-246，ADX-248和化学相关分子，用于潜在治疗全身和视网膜免疫介导的和代谢性疾病。我们的晚期候选产品是reproxalap，一种用于潜在治疗干眼症和过敏性结膜炎的RASP调节剂，以及ADX-2191，一种用于潜在治疗色素性视网膜炎的玻璃体内甲氨蝶呤的新型制剂。。